Cargando…
Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors
Chronic NLRP3 inflammasome activation can promote fibrosis through its production of interleukin (IL)-1β and IL-18. Conversely, recombinant human relaxin (RLX) can inhibit the pro-fibrotic interactions between IL-1β, IL-18 and transforming growth factor (TGF)-β1. Here, the broader extent by which RL...
Autores principales: | Tapia Cáceres, Felipe, Gaspari, Tracey A., Hossain, Mohammed Akhter, Samuel, Chrishan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266307/ https://www.ncbi.nlm.nih.gov/pubmed/35806076 http://dx.doi.org/10.3390/ijms23137074 |
Ejemplares similares
-
Relaxin Can Mediate Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3 Inflammasome at the Level of Caspase-1
por: Pinar, Anita A., et al.
Publicado: (2020) -
The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate
por: Wang, Chao, et al.
Publicado: (2016) -
Anti-fibrotic Potential of AT(2) Receptor Agonists
por: Wang, Yan, et al.
Publicado: (2017) -
Synthetic Covalently Linked Dimeric Form of H2 Relaxin Retains Native RXFP1 Activity and Has Improved In Vitro Serum Stability
por: Nair, Vinojini B., et al.
Publicado: (2015) -
Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism
por: Yuan, Shuai, et al.
Publicado: (2023)